Additive effect of Lactobacillus acidophilus L-92 on children with atopic dermatitis concomitant with food allergy
- 2019-04
- Asia Pacific Allergy 9(2)
- Joan Nakata
- Tatsuhiko Hirota
- Harue Umemura
- T. Nakagawa
- N. Kando
- M. Futamura
- Yasunori Nakamura
- Komei Ito
- PubMed: 31089460
- DOI: 10.5415/apallergy.2019.9.e18
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 59
- Population
- Young children with AD and diagnosed or suspected FA
- Methods
- Randomized Controlled Trial
- Rigorous Journal
Abstract
Background: Atopic dermatitis (AD) in infants is often related to food allergies (FA). The beneficial effects of lactic acid bacteria towards allergic diseases have been reported, but there are few reports on their effect and preferable dosages on AD in young children with concomitant FA.
Objective: To examine additional effects of two different dose of paraprobiotic Lactobacillus acidophilus L-92 (L-92) on the clinical treatment in young children afflicted by AD with diagnosed or suspected FA.
Methods: Fifty-nine AD young children from 10 months to 3 years old, with FA or who had not started to ingest specific food(s) because of high specific IgE levels, were recruited and randomly allocated into L-92 group (daily intake of 20 mg L-92/day) and placebo group. Participants were given test sample with conventional treatment for AD over a 24-week period. The severity of eczema was evaluated using SCORing Atopic Dermatitis (SCORAD) index before intervention, and at 4, 12, and 24 weeks after intervention.
Results: After 24 weeks of intervention, a significant decrease in SCORAD was observed only in the L-92 group when compared with the baseline values. Significant decreases in thymus and activation-regulated chemokine (TARC) and total IgE were also detected 24 weeks after intake in the L-92 group compared with the placebo group.
Conclusion: It was suggested that intake of sufficient amounts of L-92 works as an adjunctive treatment of young children afflicted by AD with diagnosed or suspected FA.
Keywords: Atopic dermatitis; Food sensitivity; Lactobacillus acidophilus.
Research Insights
After 24 weeks of intervention, a significant decrease in SCORAD was observed only in the L-92 group when compared with the baseline values.
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 20 mg L-92/day
After 24 weeks of intervention, a significant decrease in SCORAD was observed only in the L-92 group when compared with the baseline values.
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 20 mg L-92/day
Significant decreases in thymus and activation-regulated chemokine (TARC) and total IgE were also detected 24 weeks after intake in the L-92 group compared with the placebo group.
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 20 mg L-92/day
After 24 weeks of intervention, a significant decrease in SCORAD was observed only in the L-92 group when compared with the baseline values.
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 20 mg L-92/day
Significant decreases in thymus and activation-regulated chemokine (TARC) and total IgE were also detected 24 weeks after intake in the L-92 group compared with the placebo group.
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 20 mg L-92/day
Significant decreases in thymus and activation-regulated chemokine (TARC) and total IgE were also detected 24 weeks after intake in the L-92 group compared with the placebo group.
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 20 mg L-92/day
Adverse Events Reported
No abstract text explicitly mentions adverse events, side effects, or tolerability. The study only reports efficacy outcomes (SCORAD, TARC, total IgE) without any mention of safety findings.
- Finding
- Reported